Related Experiment Video
Updated: Feb 11, 2026

Perspectives on Neuroscience
Published on: July 31, 2007
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Andrew Kyle Henderson Robertson1,2, Caterina Fortunata Ramogida1, Paul Schaffer1,3
1Life Sciences Division, TRIUMF, Vancouver BC, Canada.
Background:
The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.
Objectives:
Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields.
Results:
Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada's particle accelerator centre - aim to address these issues.
Related Concept Videos
Socioemotional Experience and Gender Development
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Sustainable Development
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality

